证券代码：600080 证券简称：金花股份 公告编号：临 2025-007 金花企业（集团）股份有限公司 关于高级管理人员、职工监事辞职及补选职工监事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、高级管理人员及职工代表监事辞职情况 金花企业（集团）股份有限公司（以下简称"公司"）董事会于近日收到 公司副总经理宋燕萍女士递交的书面辞职报告，宋燕萍女士因个人原因辞去副 总经理职务。该辞职报告自送达公司董事会之日起生效。 公司监事会于近日收到公司职工代表监事石智华先生递交的书面辞职报告， 石智华先生因个人工作调整原因辞去职工代表监事职务，该辞职报告将自公司 职工代表大会选举产生新的职工代表监事后生效。 宋燕萍女士、石智华先生在公司任职期间恪尽职守、勤勉尽责，公司对宋 燕萍女士、石智华先生长期以来为公司发展所做出的努力与贡献表示衷心感谢！ 二、职工代表监事补选情况 根据《公司法》、《公司章程》的有关规定，为保证监事会正常运作，公 司于 2025 年 2 月 13 日召开职工代表大会，补选孙明先生为公司第十届监事会 ...

证券代码：600080 证券简称：金花股份 公告编号：2025-003 金花企业（集团）股份有限公司 持股 5%以上股东集中竞价减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，金花企业（集团）股份有限公司（以下简称"公司"） 持股 5%以上股东新余金煜企业管理有限公司（以下简称"新余金煜"）持有公司 无限售流通股份 18,797,000 股，占公司股本总数的 5.04%。 集中竞价减持计划的主要内容 股东新余金煜通过集中竞价的方式在 3 个月内减持其所持有的公司无限售 流通股份不超过 3,732,700 股，占公司股本总数不超过 1%。 一、集中竞价减持主体的基本情况 上述股东通过集中竞价交易方式减持的，在任意连续 90 个自然日内减持的股份总数不 超过公司股份总数的 1%，减持期间为自公司公告披露之日起 15 个交易日后的三个月内。 (一)相关股东是否有其他安排 □是 √否 (二)大股东此前对持股比例、持股数量、持股期限、减持方式、减持数量、减 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 65 million and 82 million yuan, indicating a turnaround from a loss in the previous year [3]. - The projected net profit after deducting non-recurring gains and losses is estimated to be between 15 million and 19 million yuan, representing an increase of 1,199.53 thousand to 1,599.53 thousand yuan, or a year-on-year growth of 399.21% to 532.34% [4]. - The previous year's net profit attributable to shareholders was a loss of 42.89 million yuan, with a total profit of -41.05 million yuan [5]. Revenue and Profit Drivers - The company's main business revenue grew approximately 3% compared to the same period last year, contributing to the increase in net profit [7]. - The disposal of 100% equity in a subsidiary, Jinhua International Hotel Co., Ltd., resulted in an investment income of approximately 36.55 million yuan, significantly impacting the profit forecast [7]. - The difference between the initial cost and the book value at the time of disposal of the subsidiary added 26.00 million yuan to the taxable income, reducing income tax expenses by approximately 39.00 million yuan [7]. - The company reported a decrease in litigation payments and provisions related to minority shareholders compared to the previous year, further supporting the profit increase [7]. Caution and Risks - The performance forecast is based on preliminary calculations and has not been audited, highlighting the need for caution among investors [9]. - The company has communicated with its annual audit accountants regarding the uncertainties related to the tax implications of the subsidiary's disposal [8]. - Investors are advised to pay attention to investment risks as the forecast data is subject to change pending the audited financial report [9].

Financial Performance - Net profit attributable to shareholders in 2023 was -42.89 million yuan, a significant decrease compared to the previous year[16] - Operating income for 2023 was 565.40 million yuan, with Q4 contributing the highest at 162.60 million yuan[33] - Basic earnings per share in 2023 was -0.1149 yuan, a decrease of 228.24% compared to 2022[30] - Weighted average return on equity (ROE) in 2023 was -2.58%, a decrease of 4.58 percentage points from 2022[30] - Revenue for 2023 was 565,403,410.11 yuan, a decrease of 2.41% compared to 2022[48] - Net profit attributable to shareholders in 2023 was -42,890,580.25 yuan, a significant decrease of 228.19% compared to 2022[48] - Net cash flow from operating activities in 2023 increased by 15.16% to 60,548,425.38 yuan compared to 2022[48] - Total assets at the end of 2023 increased by 6.79% to 2,108,551,141.95 yuan compared to the end of 2022[48] - Revenue for 2023 was 559,993,170.71 RMB, a slight decrease from 565,071,937.12 RMB in 2022[172] - Operating costs for 2023 were 129,653,842.76 RMB, compared to 128,000,047.29 RMB in 2022[172] - Net profit for 2023 was -20,290,434.95 RMB, a significant decline from 34,373,694.03 RMB in 2022[173] - Cash flow from operating activities in 2023 was 60,548,425.38 RMB, up from 52,578,993.55 RMB in 2022[178] - Cash flow from investing activities in 2023 was 137,760,856.38 RMB, down from 229,868,264.17 RMB in 2022[178] - Sales expenses for 2023 were 338,641,292.73 RMB, slightly lower than 344,947,895.90 RMB in 2022[172] - R&D expenses for 2023 were 15,089,765.04 RMB, a slight decrease from 15,493,151.13 RMB in 2022[172] - Total comprehensive income for 2023 was -22,738,712.81 RMB, compared to 28,461,853.74 RMB in 2022[173] - Cash received from sales of goods and services in 2023 was 576,518,148.48 RMB, down from 598,629,497.07 RMB in 2022[175] - Cash paid for goods and services in 2023 was 65,138,534.78 RMB, slightly higher than 64,191,860.63 RMB in 2022[178] Non-Recurring Items and Impairments - Non-recurring profit and loss items amounted to -45.90 million yuan in 2023, significantly impacting net profit[33] - The company faced significant credit impairment losses of 8.36 million yuan in 2023[33] - Non-recurring losses in 2023 amounted to -45,895,299.40 yuan, primarily due to changes in fair value of financial assets and litigation-related losses[58] - The company's trading financial assets decreased by 88,313,324.28 yuan in 2023, impacting profits by -46,093,976.24 yuan[54] - The company's other equity instrument investments decreased by 17,069,600.00 yuan in 2023[54] - The company's accounts receivable financing decreased by 7,821,038.13 yuan in 2023[54] Business Segments and Market Share - Orthopedics segment revenue: 434.62 million RMB with a gross margin of 85.90%, a slight decrease of 0.28% YoY[83] - Immunology segment revenue: 73.97 million RMB with a gross margin of 53.03%, decreased by 2.02% YoY[83] - Pediatrics segment revenue: 8.16 million RMB, increased by 16.12% YoY with a gross margin of 52.03%[83] - General medicine segment revenue: 43.24 million RMB, decreased by 7.41% YoY with a gross margin of 31.25%[83] - Jintiange Capsule maintained a leading market share of 37.81% in the osteoporosis category of traditional Chinese medicine in key city public hospitals in the first half of 2023[80] - Jintiange Capsule has been included in clinical guidelines and consensus by authoritative institutions such as the National Health Commission and the National Administration of Traditional Chinese Medicine[80] - Osteoporosis drug market share: Jintiange Capsules dominate with 37.81% market share, followed by Gukang Capsules at 10.79% and Gusongbao Capsules at 11.17%[81] - The company's leading product, Jintiange Capsule, has maintained a leading market share in the osteoporosis drug category in key city public hospitals from 2018 to the first half of 2023[103] R&D and Innovation - R&D and product marketing were key focus areas in 2023, though specific details were not provided[37][38] - R&D investment accounted for 3.39% of the parent company's operating income[70] - R&D personnel accounted for 16.00% of the parent company's total workforce[70] - R&D investment: 18.99 million RMB, accounting for 3.36% of total revenue, in line with industry average[87] - The company's R&D investment in 2023 was 47,988.15 million RMB, accounting for 4.97% of its operating revenue[110] - The average R&D investment in the industry was 31,222.82 million RMB, with the company's R&D investment accounting for 3.36% of its operating revenue[110] - The company's R&D investment capitalisation ratio was 20.58%, higher than the industry average of 19.62%[110] - The company invested 1,540.10 million RMB in research and development for marketed drug expansion, with a capitalisation amount of 368.08 million RMB[111] - The company's investment in artificial tiger bone powder research was 171.79 million RMB, with a capitalisation amount of 22.85 million RMB[111] Investments and Subsidiaries - The company's trading financial assets had an initial balance of 145,140,498.91 yuan, with a fair value change loss of -20,035,459.74 yuan during the period[135] - The company sold 100% equity of Jin Hua International Hotel Co., Ltd. for a total consideration of RMB 344.5263 million, with RMB 175.71 million (51%) received by the end of the reporting period[138] - The company transferred 8.39% equity of Chongqing Pharmaceutical Group Shaanxi Co., Ltd. for RMB 14.18 million, completing the transaction in October 2023[138] - The company's investment in Ganfeng Lithium (002460) resulted in a gain of RMB 9.11998552 million, with a final book value of RMB 1.1910384 million[136] - The company's investment in BYD (002594) incurred a loss of RMB 5.65124493 million, with a final book value of RMB 24.453 million[136] - The company's investment in Hengsheng Electronics (600570) resulted in a loss of RMB 3.08133788 million, with a final book value of RMB 11.5792074 million[136] - The company's investment in Shede Liquor (600702) incurred a loss of RMB 9.6517786 million, with a final book value of RMB 2.97836 million[136] - The company's investment in Dongfang Cable (603606) resulted in a gain of RMB 46,070.71[136] - The company's investment in Dongfang Securities (600958) resulted in a gain of RMB 39,294.87[136] - The company's investment in Enjie Co., Ltd. (002812) resulted in a gain of RMB 65,658.08[136] - The company's investment in GAC Group (601238) resulted in a gain of RMB 2,902.18[136] - The company's total investment in real estate and pharmaceutical subsidiaries amounted to 336,000,000 RMB, with a total loss impact of -117,320.24 RMB[115] - The company's securities investment at the end of the period was 56,827,174.63 RMB, with a purchase amount of 1,505,666,597.57 RMB and a sale/redemption amount of 1,573,944,462.11 RMB[115] - Jin Hua International Hotel Co., Ltd. reported a net loss of -1,819.34 million yuan, with total assets of 33,390.71 million yuan and net assets of 30,268.21 million yuan[120] - Xi'an Jishitang Pharmaceutical Co., Ltd. reported a net loss of -37.61 million yuan, with total assets of 73.03 million yuan and net assets of -46.11 million yuan[120] - Xi'an Jin Hua Tiange Pharmaceutical Co., Ltd. reported a net loss of -339.08 million yuan, with total assets of 348.76 million yuan and net assets of -338.24 million yuan[120] - Shaanxi Yizhen Trading Co., Ltd. reported a net loss of -57.24 million yuan, with total assets of 1.16 million yuan and net assets of -57.34 million yuan[120] - Shaanxi Cuibin Management Consulting Co., Ltd. reported a net loss of -1.94 million yuan, with total assets of 0.96 million yuan and net assets of -2.04 million yuan[120] Cash Flow and Financial Position - Net cash flow from operating activities in 2023 increased by 15.16% to 60,548,425.38 yuan compared to 2022[48] - Total assets at the end of 2023 increased by 6.79% to 2,108,551,141.95 yuan compared to the end of 2022[48] - Monetary funds increased by 42.80% to 620,449,552.12 yuan, accounting for 29.43% of total assets[73] - Long-term equity investments increased by 54.85% to 495,208,685.38 yuan, accounting for 23.49% of total assets[73] - The company's cash and cash equivalents increased by 187,094,086.50 RMB in 2023, reaching a total of 619,732,781.67 RMB at the end of the year[148] - Operating cash flow for 2023 was 60,205,257.58 RMB, a slight increase from 52,368,270.85 RMB in 2022[148] - Investment cash flow for 2023 was 137,917,142.96 RMB, a decrease from 229,832,473.17 RMB in 2022[151] - Financing cash flow for 2023 was -10,518,846.02 RMB, compared to -7,112,015.05 RMB in 2022[151] - The company received 175,405,390.44 RMB from borrowing in 2023[148] - Sales revenue from goods and services in 2023 was 572,414,629.62 RMB, slightly lower than 585,760,255.79 RMB in 2022[148] - The company paid 82,771,090.93 RMB to employees in 2023, up from 70,871,981.27 RMB in 2022[148] - Total cash inflow from investment activities in 2023 was 2,317,554,738.41 RMB, compared to 1,586,147,165.85 RMB in 2022[151] - The company's total assets at the end of 2023 were 1,638,426,525.45 RMB[155] - Net profit attributable to parent company owners in 2023 was 444,384,127.77 RMB[155] Equity and Comprehensive Income - Total owner's equity: 1.65 billion RMB, decreased by 22.74 million RMB compared to the beginning of the year[88][90] - Comprehensive income: -22.74 million RMB, mainly due to a decrease in other comprehensive income and undistributed profits[88] - Capital reserve: 779.94 million RMB, unchanged from the beginning of the year[88] - Surplus reserve: 124.97 million RMB, increased by 704,323.50 RMB compared to the beginning of the year[90] - The company's total owner's equity at the beginning of the year was RMB 1,648,339,243.16, with a capital reserve of RMB 779,935,778.81 and undistributed profits of RMB 484,445,082.74[92] - During the reporting period, the company's comprehensive income decreased by RMB 5,911,840.29, while undistributed profits increased by RMB 30,936,324.63, resulting in a net increase in owner's equity of RMB 28,461,853.74[92] - The company's total owner's equity at the end of the period was RMB 1,676,801,096.90, with a capital reserve of RMB 779,935,778.81 and undistributed profits of RMB 515,381,407.37[95] - The company's equity at the end of the period was RMB 1.68 billion, with a decrease of RMB 116.05 million in retained earnings[160] - The company's equity at the beginning of the period was RMB 1.66 billion, with a decrease of RMB 110.14 million in retained earnings[159] - The company's total owner's equity at the beginning of the year was 1,683,765,383.56, with a decrease of 45,338,858.11 during the period[188] - The comprehensive income for the period showed a loss of 45,338,858.11, primarily due to a decrease in other comprehensive income of 9,491,512.86 and a reduction in undistributed profits of 36,551,668.75[188] - The company's capital reserve (capital surplus) stood at 821,345,676.32 at the beginning of the year[188] - The company's undistributed profits at the beginning of the year were 480,935,796.52, which decreased by 42,890,580.25 during the period[188] - The company's other comprehensive income showed a negative balance of 116,054,721.41 at the beginning of the year, which further decreased by 2,448,277.86 during the period[188] Corporate Governance and Regulatory Issues - The company did not implement any profit distribution or capital reserve to share capital conversion plan for 2023 due to negative net profit[16] - The company resolved a historical illegal guarantee risk in 2023, with full deposit received and risk eliminated[18] - The company adjusted its marketing structure to stabilize market share and deepen core channels, focusing on academic and value-driven marketing[57] - In 2023, the company faced challenges from industry policies and competition, but focused on innovation and compliance transformation[61] - The company plans to focus on core business, deepen marketing management, and strengthen communication mechanisms in 2024, aiming for comprehensive development and market expansion[123] - The company transferred 36% of its equity in Shaanxi Herunyi Industrial Co., Ltd. for 1 yuan and 40% for 1 yuan, reducing its stake to 24% and investing a total of 166 million yuan in 2023[134] - Board of Directors and senior management changes, including the election of new Chairman Xing Yajiang and Vice Chairman Xing Boyue[199] - The company received a public reprimand from the Shanghai Stock Exchange for its current actual controller and Vice President Xing Boyue[199] - The company was issued a warning letter by the Shaanxi Regulatory Bureau of the China Securities Regulatory Commission[199] - The company and its Board Secretary Sun Ming were criticized by the Shanghai Stock Exchange[199] Industry and Market Trends - The osteoporosis drug market in China has shown a steady growth trend, with the market size increasing from RMB 9.82 billion in 2017 to RMB 11.36 billion in 2022[101] - In 2022, the prevalence of osteoporosis in the population aged 50 and above was 19.2%, with a higher prevalence in females (32.1%) compared to males (6.9%)[101] - The Chinese government has introduced multiple policies to promote the development of the pharmaceutical industry, including the "High-Quality Development Action Plan for the Pharmaceutical Industry (2023-2025)"[98] - The aging population in China is increasing, with 280.04 million people aged 60 and above, accounting for 19.8% of the total population in 2022[101] - The company operates in the pharmaceutical manufacturing industry, specifically in the production of traditional Chinese medicine for orthopedic treatment[100] - The company's main product, Jintiange Capsules, achieved a total actual procurement volume of 846,000 boxes (24 capsules/box) with a bid price range of 40.31-43.38 RMB per box[105] - Jintiange Capsules (36 capsules/box) had a total actual procurement volume of 311,000 boxes with a bid price range of 60.46-65.08 RMB per box[105] - Transfer Factor Capsules (24 capsules/box) recorded a total actual procurement volume of 540,000 boxes with a bid price range of 18.3-19.02 RMB per box[105] Board and Committee Activities - The company's audit committee held 6 meetings during the reporting period, focusing on annual reports, financial statements, and internal control evaluations[191] - The company's board of directors approved the 2022 annual report, financial statements, and profit distribution plan during the 27th meeting of the 9th board on April 26, 2023[184] - The company's board of directors approved the application for comprehensive credit from banks and the establishment of new fundraising accounts during the 26th meeting of the 9th board on January 13, 2023[184] - The company's audit committee reviewed and approved the 2023 semi-annual report and the

Financial Performance - Operating revenue for the reporting period was CNY 255,369,543.71, down 1.29% year-on-year[11] - Net profit attributable to shareholders of the listed company was CNY 1,263,503.00, a significant decrease of 94.12% compared to the same period last year[11] - Basic earnings per share were CNY 0.0034, down 94.09% from CNY 0.0575 in the same period last year[11] - The weighted average return on net assets decreased by 1.21 percentage points to 0.08%[11] Cash Flow - The net cash flow from operating activities was CNY -34,391,321.39, indicating a substantial decline from CNY 24,253,247.16 in the previous year[11] Assets and Shareholder Information - Total assets at the end of the reporting period were CNY 1,938,591,247.08, a decrease of 1.81% compared to the previous year-end[11] - The number of shareholders at the end of the reporting period was 28,078[20] - The top shareholder, Xing Boyue, holds 19.63% of the shares, totaling 73,272,546 shares, with 53,273,495 shares pledged[20] Corporate Actions - The company did not conduct profit distribution or capital reserve transfer to increase share capital during the reporting period[10] - The company reported no significant changes in its operating conditions or major events that would impact future operations[14]

Financial Performance - The company's operating revenue for Q3 2023 was ¥147,435,488.04, representing a decrease of 10.34% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2023 was -¥6,257,459.32, a decline of 160.41% year-over-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,180,388.03, down 72.70% from the previous year[7]. - The basic earnings per share for Q3 2023 was -¥0.0168, a decrease of 160.42% compared to the same period last year[10]. - The weighted average return on equity was -0.38%, a decrease of 1.00 percentage points year-over-year[10]. - Net profit for the third quarter of 2023 was CNY -4,993,956.32, a significant decline compared to CNY 31,829,432.97 in the same quarter of 2022[35]. - The net profit attributable to the parent company's shareholders for the current period is -4,993,956.32, compared to a profit of 31,829,432.97 in the same period last year[38]. - The basic and diluted earnings per share for the current period are both -0.0134, down from 0.0853 in the previous year[38]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,050,925,875.34, an increase of 3.87% compared to the end of the previous year[10]. - Total assets as of the end of the reporting period were CNY 2,050,925,875.34, an increase from CNY 1,974,418,631.97 at the end of the previous year[32]. - Total liabilities increased to CNY 372,154,159.54 in 2023 from CNY 290,653,248.41 in 2022, marking a rise of 28.0%[32]. - The company’s total equity decreased slightly to CNY 1,678,771,715.80 from CNY 1,683,765,383.56, indicating a decline of 0.3%[32]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥11,949,314.66, a decrease of 28.52% compared to the same period last year[10]. - Cash inflow from operating activities for the first three quarters of 2023 is 441,830,298.33, slightly up from 441,329,151.28 in the same period last year[41]. - The net cash flow from operating activities is -11,949,314.66, compared to -9,297,386.75 in the previous year[41]. - Cash inflow from investment activities totals 1,446,976,524.92, compared to 983,848,470.29 in the same period last year[43]. - The net cash flow from investment activities is -48,514,725.24, down from a positive 64,166,189.36 in the previous year[43]. - Cash inflow from financing activities is 175,405,390.44, with a net cash flow of 67,366,210.20, compared to -176,530.76 in the previous year[43]. - The ending cash and cash equivalents balance is 439,540,865.47, up from 213,132,731.53 at the end of the previous year[43]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,854, with the top 10 shareholders holding a combined 56.4% of shares[17]. - The largest shareholder, Xing Boyue, holds 73,272,546 shares, representing 19.63% of total shares[17]. Research and Development - Research and development expenses increased by 37.95% year-to-date, reflecting higher investment in ongoing projects[14]. - Research and development expenses increased to CNY 8,860,272.09 in 2023 from CNY 6,422,923.40 in 2022, representing a growth of 38.0%[35]. - The company has signed a cooperation agreement to establish the "Western Jinhua Academician Workstation" with Academician Wang Songling's team, focusing on the development of a new drug for treating radiation-induced salivary gland damage[22]. - The new drug research project is still in the early stages, and its success is uncertain due to various influencing factors[22]. - The establishment of the workstation is not expected to have a significant short-term impact on the company's financial status or operating performance[22]. Other Financial Metrics - The company reported a significant decrease in government subsidies received, down 80.05% year-to-date[14]. - The company reported a decrease in sales expenses to CNY 240,889,890.91 from CNY 247,754,430.88, a reduction of 2.8%[35]. - The company's financial expenses showed a significant improvement, with a net financial income of CNY -1,573,662.54 compared to CNY -3,753,716.37 in the previous year[35]. - The company reported a significant reduction in other receivables, decreasing from ¥165,246,367.76 to ¥35,739,684.66, a decline of approximately 78.4%[27]. - The inventory increased to ¥28,438,540.88 from ¥25,150,619.56, reflecting an increase of about 9.1%[27]. - The company has not executed any mergers or acquisitions during the reporting period, with the merged entity reporting a net profit of 0[40].

证券代码：600080 股票简称：金花股份 编号：临 2024-058 金花企业（集团）股份有限公司 第十届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 金花企业（集团）股份有限公司第十届董事会第十五次会议通知于 2024 年 12 月 23 以电子邮件及微信方式发出，会议于 2024 年 12 月 25 日以通讯表决方 式召开，应参与表决董事 7 人，实际表决人数 7 人，符合《公司法》和《公司章 程》的有关规定。经讨论表决，会议通过如下决议。 二、董事会会议审议情况 （一）通过《关于会计差错更正的议案》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 具 体 内 容 详 见 公 司 同 日 在 上 海 证 券 报 及 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《金花企业（集团）股份有限公司关于会计差错更正 的公告》。 本议案已经公司第十届董事会审计委员会审议通过。 （二）通过《关于部分募集资金投资项目延期的议案》 表决结果 ...

证券代码：600080 股票简称： 金花股份 编号：临 2024-060 金花企业（集团）股份有限公司 关于部分募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担个别及连带责任。 金花企业（集团）股份有限公司 （以下简称"公司"）于 2024 年 12 月 25 日召开 第十届董事会第十五次会议、第十届监事会第十次会议，审议通过了《关于部分募集资 金投资项目延期的议案》，同意公司在不改变募集资金投资项目投资内容、投资总额、 实施主体等情况下，根据募集资金投资项目的实施进度，对部分募集资金投资项目进行 延期。公司监事会对该事项发表了同意意见，公司保荐机构国金证券股份有限公司（以 下简称"国金证券"或"保荐机构"）出具了明确的核查意见。该事项无需提交公司股 东大会审议。现就相关事项公告如下： 一、募集资金基本情况 经中国证监会《关于核准金花企业（集团）股份有限公司非公开发行股票的批复》 （证监许可[2017]1648 号）核准，金花企业（集团）股份有限公司（以下简称"公司"） 发行股票 67,974,413 股（A ...

证券代码：600080 股票简称：金花股份 编号：临 2024-061 金花企业（集团）股份有限公司 第十届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 监事会会议召开情况 金花企业（集团）股份有限公司第十届监事会第十次会议通知于 2024 年 12 月 23 日以电子邮件及微信方式发出，会议于 2024 年 12 月 25 日以现场方式在公 司会议室召开。应出席监事 3 人,实际出席 3 人，会议由监事会主席马斌先生主 持，本次会议的召集召开符合《公司法》和《公司章程》的有关规定，经讨论表 决，通过如下决议。 二、监事会会议审议情况 （一）通过《关于会计差错更正的议案》 表决情况：同意票 3 票，反对票 0 票，弃权票 0 票 综上，监事会同意公司本次部分募集资金投资项目延期事项。 特此公告。 金花企业（集团）股份有限公司监事会 2024 年 12 月 26 日 1、公司本次会计差错更正事项符合《企业会计准则第 28 号—会计政策、会 计估计变更和差错更正》、《公开发行证券的公司信息披 ...